Strides Arcolab, a Rs.2,575 crore plus pharma major, has posted impressive performance during the year ended December 2012 on account of significant rise in licensing income, forex gains, US FDA approvals for two new facilities and product launches. The company's consolidated net profit went up by 83 per cent to Rs.223 crore from Rs.122 crore. Its EBDITA also moved up by 30.8 per cent to Rs.518 crore from Rs.396 crore. The earnings per share improved smartly to Rs.38.65 as against Rs.26.11 in the last year. The exchange gains increased sharply to Rs.51.43 crore from Rs.4.76 crore in the previous year, which inflated its net profit significantly. The company declared equity dividend of 20 per cent for the year 2011.

Strides' consolidated net sales touched to Rs.2,525 crore during the year ended December 2012 from Rs.1,696 crore, registering a strong growth of 48.9 per cent. The consolidated revenues include R&D/licensing income of Rs.528 crore as compared to Rs.363 crore in the previous year, a significant growth of 45.9 per cent. The pharma sales increased by 44.5 per cent to Rs.1,553 crore from Rs.1,075 crore and worked out to 60.3 per cent of total net sales. The sales of specialties segment moved up by 48.2 per cent to Rs.1,024 crore from Rs.691 crore.

Arun Kumar, vice chairman and group CEO, said, “Our results showcase our commitment to deliver value to our stakeholders through superior financial performance. With significant plant and product approvals, year 2011 has been testimonial to our focus and vigour in compliance in a challenging regulatory landscape.”

The company received US FDA approval for its new sterile facility and new oncology facility at Bangalore during 2011. The company filed 31 products in US and received approval for 27 products. The total filings reached at 183 with cumulative approval of 84 products. It commercialized 13 products in US during 2011. In other established markets, Strides has filed 76 products and cumulative filing reached at 314 products. It filed 115 products in emerging markets with 91 approvals. Its total cumulative products filing in emerging market reached at 1,541.

The company's standalone net sales increased by 41.8 per cent during 2011 to Rs.716 crore from Rs.505 crore in the previous year. Its standalone net profit grew by 60.4 per cent to Rs.117.92 crore from Rs.73.56 crore.